3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Smoldering Multiple Myeloma
1
Multiple Myeloma
1
Interventions
Dexamethasone
11
Lenalidomide
9
Calcium Dobesilate
5
carfilzomib
4
daratumumab
3
isatuximab
2
iberdomide
2
elotuzumab
2
dexamethasone acetate
2
dexamethasone 21-phosphate
2
auricularum
2
Leflunomide
2
Denosumab
2
selinexor
1
pomalidomide
1
piperine
1
ixazomib
1
ibrutinib
1
fludarabine phosphate
1
fludarabine
1
Simvastatin
1
Nivolumab
1
Metformin
1
Melphalan
1
IPH-2101
1
Gene Expression Profiling
1
Fatty Acids, Omega-3
1
Cyclophosphamide
1
Curcumin
1
Cholestyramine Resin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Smoldering Multiple Myeloma
×
IPH-2101
×
Clear all
NCT01222286
2026-05-14
KIRMONO
Innate Pharma
Phase 2
Completed
30 enrolled
10 charts